Bioverativ(BIVV) To Be Acquired By Sanofi(SNY) At Huge 64% Premium

It was just one year ago when Biogen(BIIB) spun off hemophilia and blood disorder specialist Bioverativ(BIVV). With the stock trading in the 40s post-spin, we highlighted some disparate analyst opinions of the spin. The most bullish, Gabelli & Company, has a price target of $58 for Bioverativ stock.  This past Friday, Bioverativ stock closed at $64.11, above Gabelli’s… Read More »